Lu Xiao, Zhou Dong, Hou Bing, Liu Quan-Xing, Chen Qian, Deng Xu-Feng, Yu Zu-Bin, Dai Ji-Gang, Zheng Hong
Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Cancer Manag Res. 2018 May 16;10:1231-1241. doi: 10.2147/CMAR.S156530. eCollection 2018.
Chemotherapy is still the primary adjuvant strategy of cancer therapy; however, the emergence of multi-drug resistance has been a cause for concern. Autophagy has been demonstrated to have a protective role against chemotherapeutic drugs in cancer cells, and autophagy inhibition is generally considered to be a promising therapeutic strategy. However, the paucity of effective and specific autophagy inhibitors limits its application.
The objective of this study was to explore the effect of DCA, small molecular anti-tumor agent, on the autophagy regulation and chemosensitization in NSCLC cells.
We investigated the autophagy regulation of dichloroacetate (DCA) by laser confocal microscopy and western blotting in A549 and H1975 cell lines. The MTT assay and flow cytometry was performed for explore the chemosensitization effectiveness of DCA. The results were verified with subcutaneous tumor model in nude mice and the immunohistochemistry was applied for assessing the level of cell apoptosis and autophagy in vivo post treatment.
We found that DCA, which exhibited antitumor properties in various carcinoma models, induced apoptosis of non-small cell lung cancer cells (NSCLC) by inhibiting cancer cell autophagy. Furthermore, Perifosine, an AKT inhibitor, can greatly weaken the capacity of inducing apoptosis by DCA. The results indicate that the AKT-mTOR pathway, a main negative regulator of autophagy, is involved in the DCA-induced inhibition of autophagy. Then, we detected the effectiveness of autophagy inhibition by DCA. When used in co-treatment with the chemotherapeutic drug paclitaxel (PTX), DCA markedly decreased cell autophagy, enhanced apoptosis and inhibited proliferation in A549 and H1975 cells. The results of the xenograft experiment demonstrate that co-treatment of PTX and DCA can significantly decrease cell proliferation in vivo and prolong the survival of mice.
Our results suggest that DCA can inhibit cell autophagy induced by chemotherapeutics, providing a new avenue for cancer chemotherapy sensitization.
化疗仍然是癌症治疗的主要辅助策略;然而,多药耐药性的出现令人担忧。自噬已被证明在癌细胞中对化疗药物具有保护作用,自噬抑制通常被认为是一种有前景的治疗策略。然而,有效且特异性的自噬抑制剂的匮乏限制了其应用。
本研究的目的是探索小分子抗肿瘤药物二氯乙酸(DCA)对非小细胞肺癌(NSCLC)细胞自噬调节和化疗增敏的影响。
我们通过激光共聚焦显微镜和蛋白质印迹法研究了二氯乙酸(DCA)对A549和H1975细胞系自噬的调节作用。采用MTT法和流式细胞术探讨DCA的化疗增敏效果。结果在裸鼠皮下肿瘤模型中得到验证,并应用免疫组织化学法评估治疗后体内细胞凋亡和自噬水平。
我们发现,在各种癌症模型中均表现出抗肿瘤特性的DCA,通过抑制癌细胞自噬诱导非小细胞肺癌(NSCLC)细胞凋亡。此外,AKT抑制剂哌立福新可大大削弱DCA诱导凋亡的能力。结果表明,自噬的主要负调节因子AKT-mTOR通路参与了DCA诱导的自噬抑制。然后,我们检测了DCA抑制自噬的效果。当与化疗药物紫杉醇(PTX)联合使用时,DCA显著降低了A549和H1975细胞中的自噬,增强了凋亡并抑制了增殖。异种移植实验结果表明,PTX与DCA联合治疗可显著降低体内细胞增殖并延长小鼠生存期。
我们的结果表明,DCA可抑制化疗药物诱导的细胞自噬,为癌症化疗增敏提供了一条新途径。